BRAF and glioblastoma: This cohort comprised 53 IDH1/2-mutant astrocytomas, 19 histone-mutant tumors, 7 with MAPK pathway alterations (BRAF, NF1), 19 GBM (13 pTERTmt) and 2 OD (1pTERTmt).